Sugi Predict

Sugi Predict / Compounds / SCHEMBL1241322

SCHEMBL1241322

SCHEMBL1241322

CN(C)Cc1c[nH]c2cc(F)ccc12

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GPR84 Q9NQS5 3/20 0.67
▸ HTR1A P08908 1/20 0.60
▸ KDM4E B2RXH2 1/20 0.60
▸ MEN1 O00255 1/20 0.60
▸ ALDH1A1 P00352 1/20 0.60
▸ CYP3A4 P08684 1/20 0.60
▸ CYP2D6 P10635 1/20 0.60
▸ TSHR P16473 1/20 0.60
▸ CYP2C19 P33261 1/20 0.60
▸ KMT2A Q03164 1/20 0.60
▸ HSD17B10 Q99714 1/20 0.60
▸ HTR2A P28223 6/20 0.59
▸ MPO P05164 3/20 0.55
▸ SLC6A4 P31645 2/20 0.52
▸ HTR2C P28335 3/20 0.48
▸ HTR2B P41595 2/20 0.48
▸ ACHE P22303 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3216581 0.87 MPO (0.72) GPR84HTR1AKDM4EMEN1ALDH1A1
SCHEMBL23927849 0.84 MPO (0.78) GPR84HTR1AHTR2AMPOSLC6A4
SCHEMBL29435343 0.84 MPO (0.78) GPR84HTR1AHTR2AMPOSLC6A4
SCHEMBL5273347 0.81 KDM4E (0.62) GPR84HTR1AKDM4EMEN1ALDH1A1
SCHEMBL27510343 0.81 TDO2 (0.54) GPR84HTR1AKDM4EMEN1ALDH1A1
SCHEMBL6846117 0.81 GPR84 (0.73) GPR84HTR1ATSHRHTR2AMPO
SCHEMBL27929607 0.80 GPR84 (1.00) GPR84HTR1AMEN1CYP3A4KMT2A
SCHEMBL3018247 0.80 SLC6A4 (0.68) GPR84HTR1AKDM4EMEN1ALDH1A1
SCHEMBL29507897 0.80 MEN1 (0.60) GPR84HTR1AKDM4EMEN1ALDH1A1
SCHEMBL4857335 0.80 MEN1 (0.60) GPR84HTR1AKDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240408064-A1 RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF GENETOLEAD INC. (CA) 2024-12-12 — — US disclosed
EP-3230265-A1 A PROCESS FOR THE MANUFACTURE OF IDALOPIRDINE H. Lundbeck A/S (DK) 2017-10-18 — — EP disclosed
US-9382205-B2 Processes for the manufacture of a pharmaceutically active agent H. LUNDBECK A/S (DK) 2016-07-05 — — US disclosed
US-9382205-B2 Processes for the manufacture of a pharmaceutically active agent H. LUNDBECK A/S (DK) 2016-07-05 — — US disclosed
US-9382205-B2 Processes for the manufacture of a pharmaceutically active agent H. LUNDBECK A/S (DK) 2016-07-05 — — US disclosed
US-20160168089-A1 PROCESS FOR THE MANUFACTURE OF IDALOPIRDINE LUNDBECK A/S (DK) 2016-06-16 — — US disclosed
US-20160168089-A1 PROCESS FOR THE MANUFACTURE OF IDALOPIRDINE LUNDBECK A/S (DK) 2016-06-16 — — US disclosed
WO-2016091997-A1 A PROCESS FOR THE MANUFACTURE OF IDALOPIRDINE H. LUNDBECK A/S (DK) 2016-06-16 — — WO disclosed
US-20160168089-A1 PROCESS FOR THE MANUFACTURE OF IDALOPIRDINE LUNDBECK A/S (DK) 2016-06-16 — — US disclosed
WO-2016091997-A1 A PROCESS FOR THE MANUFACTURE OF IDALOPIRDINE H. LUNDBECK A/S (DK) 2016-06-16 — — WO disclosed
US-20050159473-A1 3-Substituted oxindole beta3 agonists SALL DANIEL J (US) 2005-07-21 — — US disclosed
US-6911463-B2 3-substituted oxindole β-3 agonists ELI LILLY AND COMPANY (US) 2005-06-28 — — US disclosed
US-20050080110-A1 Beta 3 adrenergic agonists SALL DANIEL JON (US) 2005-04-14 — — US disclosed
US-20040242668-A1 3-substituted oxindole beta-3 agonists SALL DANIEL JON (US) 2004-12-02 — — US disclosed
EP-1444224-A2 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS ELI LILLY AND COMPANY (US) 2004-08-11 — — EP disclosed
EP-1421078-A1 BETA-3 ADRENERGIC AGONISTS ELI LILLY AND COMPANY (US) 2004-05-26 — — EP disclosed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 — — EP disclosed
WO-2003016307-A1 β3 ADRENERGIC AGONISTS ELI LILLY AND COMPANY (US) 2003-02-27 — — WO disclosed
WO-2003016276-A2 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS ELI LILLY AND COMPANY (US) 2003-02-27 — — WO disclosed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242668-A1 3-substituted oxindole beta-3 agonists ADRB3, ADRB2, ADRB1 GPR84 98/4885HTR1A 347/4885KDM4E 3972/4885
US-20160168089-A1 PROCESS FOR THE MANUFACTURE OF IDALOPIRDINE ADRA2C, QDPR, ADRA1D GPR84 1542/4885HTR1A 221/4885KDM4E 3297/4885
US-20240408064-A1 RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF KRAS, NRAS, HRAS GPR84 4191/4885HTR1A 4832/4885KDM4E 4019/4885
US-20050159473-A1 3-Substituted oxindole beta3 agonists ADRB3, ADRB2, ADRB1 GPR84 106/4885HTR1A 353/4885KDM4E 3960/4885
US-20050080110-A1 Beta 3 adrenergic agonists ADRB3, ADRB2, ADRB1 GPR84 45/4885HTR1A 1067/4885KDM4E 3778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.